RA Capital Discloses New Passive Stake in Repros Therapeutics Inc (RPRX)

RA Capital Management, managed by Peter Kolchinsky, has revealed a new position in Repros Therapeutics Inc (NASDAQ:RPRX). RA Capital has disclosed a passive stake in the company, which amasses 6.2% of common stock, showed a new filing with the Securities and Exchange Commission. The position contains 1.44 million shares.

Peter Kolchinsky

Repros Therapeutics Inc (NASDAQ:RPRX) is engaged in the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

For the three month period ended December 31, 2013, the company reported a net loss of $7.1 million, or $0.31 per share, compared to a net loss of $8.0 million, or $0.47 per share, for the same period in 2012. The decrease in net loss was primarily due to reduced clinical development expenses related to Androxal, partially offset by an increase in payroll and benefits expenses. For the 12-month period ended December 31, 2013, the company reported a net loss of $27.7 million, or $1.33 per share, compared to a net loss of $18.2 million, or $1.18 per share, for 2012.

Baker Bros. Advisors, managed by Julian Baker and Felix Baker, owns 2.78 million shares of Repros Therapeutics Inc (NASDAQ:RPRX). Another investor Jacob Gottlieb’s Visium Asset Management disclosed holding 1.84 million shares of the company at the end of the fourth quarter of 2013.

Boston-based RA Capital invests in companies with promising drugs and technologies. Last month, Ra Capital disclosed owning 2.43 million shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), equivalent to 14.6% of the common stock. In addition, the fund initiated a 7.2% passive stake in Furiex Pharmaceuticals Inc (NASDAQ:FURX), the position amassing 750,000 shares. In January, Ra Capital reported selling a total of 300,000 shares of Derma Sciences Inc (NASDAQ:DSCI).

RA Capital is also a fan of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) and Sangamo Biosciences Inc. (NASDAQ:SGMO), owning 23.37 million shares and 5.23 million shares, respectively.

Disclosure: none

Recommended Reading:

Steven Cohen Ups His Bets on NQ Mobile Inc (ADR) (NQ)

Hedge Fund News: Thomas Steyer, Bill Ackman & Eric Mindich

Wexford Capital Decreases Exposure to Diamondback Energy Inc (FANG)

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!